Research on Predicting Progression to Severe COVID-19 Using PTX3
First written in FY2021. 8 of 16 entries say "Restated". Latest entry: 2026-08-13.
No other company in this theme has enough history to compare yet.
- FY2026-H1RaisedAnnual report
「Clinical performance testing of the rapid PTX3 measurement kit being developed jointly with Wakunaga Pharmaceutical Co., Ltd. has been completed as an in vitro diagnostic medical device for a type of cardiovascular disease (undisclosed), and we are currently preparing for marketing approval. PTX3 is known to increase in the blood not only with vasculitis but also with various types of inflammation, and we will continue research and development toward an in vitro diagnostic medical device for predicting the prognosis of a range of inflammatory diseases.」
The company has indicated that it will continue preparing for approval following completion of clinical performance testing while expanding the target use of the rapid PTX3 measurement kit from cardiovascular disease to prognostic prediction for a range of inflammatory diseases. - FY2025AdvancedAnnual report
「As of the end of December 2024, clinical performance testing of the rapid PTX3 measurement kit being developed jointly with Wakunaga Pharmaceutical Co., Ltd. had been completed as an in vitro diagnostic medical device for a type of cardiovascular disease (undisclosed), and we are currently preparing for marketing approval.」
The rapid PTX3 measurement kit completed clinical performance testing and advanced to the preparation stage for marketing approval. - FY2025-H1RestatedAnnual report
「We are also continuing development of the rapid PTX3 measurement kit jointly with Wakunaga Pharmaceutical Co., Ltd.」
Development of a rapid PTX3 measurement kit in collaboration with Wakunaga Pharmaceutical Co., Ltd. is ongoing. - FY2024-Q2RestatedAnnual report
「We are also continuing to jointly develop a rapid PTX3 measurement kit with Wakunaga Pharmaceutical Co., Ltd.」
Development of a rapid PTX3 measurement kit in collaboration with Wakunaga Pharmaceutical Co., Ltd. is ongoing. - FY2024-Q1RestatedAnnual report
「We are also continuing to jointly develop a rapid PTX3 measurement kit with Wakunaga Pharmaceutical Co., Ltd.」
Development of a rapid PTX3 measurement kit in collaboration with Wakunaga Pharmaceutical Co., Ltd. is ongoing. - FY2023AdvancedAnnual report
「In addition to these pipelines, we are evaluating UT28K, a super-neutralizing antibody candidate for treating various COVID-19 variants, together with the University of Toyama and Toyama Prefecture. We plan to advance development with grants from the government and other sources, and are currently analyzing animal studies conducted at the University of Toyama to verify its therapeutic effects.」
For UT28K, analysis of the animal studies conducted to verify its therapeutic effects is underway. - FY2023-Q3RestatedAnnual report
「We are continuing development, together with Wakunaga Pharmaceutical Co., Ltd., with which we have signed a joint research agreement, of a rapid PTX3 measurement kit for predicting the severity of various diseases involving vascular inflammation, including pneumonia caused by COVID-19.」
We are continuing to develop, through joint research with Wakunaga Pharmaceutical Co., Ltd., a rapid PTX3 measurement kit intended to predict the severity of various diseases involving vascular inflammation. - FY2023-Q2RestatedAnnual report
「The company entered into a joint research agreement with Wakunaga Pharmaceutical Co., Ltd. to develop a rapid PTX3 assay kit for predicting the severity of pneumonia and other diseases involving vascular inflammation, including COVID-19, and is currently proceeding with development.」
Development of a rapid PTX3 measurement kit through joint research with Wakunaga Pharmaceutical Co., Ltd. is ongoing. - FY2023-Q1RestatedAnnual report
「We are also jointly developing a rapid PTX3 measurement kit with Wakunaga Pharmaceutical Co., Ltd.」
Development of a rapid PTX3 measurement kit in collaboration with Wakunaga Pharmaceutical is ongoing. - FY2022AdvancedAnnual report
「The company entered into a joint research agreement with Wakunaga Pharmaceutical Co., Ltd. to develop a rapid PTX3 assay kit for predicting the severity of pneumonia and other diseases involving vascular inflammation, including COVID-19, and is currently proceeding with development.」
Progress was made by expanding the potential applications of PTX3 beyond COVID-19 pneumonia to various diseases involving vascular inflammation and entering into a joint research agreement with Wakunaga Pharmaceutical Co., Ltd. - FY2022-Q3ReframedAnnual report
「Regarding development of a diagnostic kit to predict the severity of pneumonia caused by COVID-19 using a PTX3 assay kit, a vascular inflammation marker, the company is considering reviewing its collaboration partners because progress has been delayed in collecting and analyzing samples by symptom category and in other work. PTX3 is a protein secreted locally at sites of inflammation, and PTX3 concentrations in the blood are known to be higher than in healthy individuals in diseases associated with inflammation, such as vascular injury and heart disease. The company aims to develop in vitro diagnostic products that can predict the prognosis of various diseases involving vascular inflammation, such as sepsis, in addition to predicting the severity of COVID-19.」
In response to delays in sample collection and analysis, the company is considering reviewing its collaboration partners, while expanding the development target beyond COVID-19 to include prognosis prediction for various diseases involving vascular inflammation, such as sepsis. - FY2022-Q2RestatedAnnual report
「The company is also developing a diagnostic kit to predict the severity of pneumonia caused by COVID-19 using a PTX3 assay kit, a vascular inflammation marker.」
The company continues to develop a diagnostic kit to predict the severity of COVID-19 pneumonia using a PTX3 assay kit. - FY2022-Q1RestatedAnnual report
「The company is also developing a diagnostic kit to predict the severity of pneumonia caused by COVID-19 using a PTX3 assay kit, a vascular inflammation marker.」
The company has reaffirmed its continued development of a diagnostic kit to predict the severity of COVID-19 pneumonia using a PTX3 assay kit. - FY2021First statedAnnual report
「The company is also developing a diagnostic kit to predict the severity of pneumonia caused by COVID-19 using a PTX3 assay kit, a vascular inflammation marker.」
Through collaboration with several university hospitals and other institutions, the company is conducting validation studies to predict disease severity and developing a diagnostic kit using PTX3.